CROI 2024 Abstract eBook

Abstract eBook

Abstract Processs

Requirements for Abstract Content Study Design: Presentations from randomized trials and cohorts should follow the ICMJE guidelines, including reporting of study designs (eg, prospective, observational, randomized, double-blind, STROBE, CONSORT, or others), statistical methods, and outcomes by demographic variables. Please also note whether the study is ongoing or completed and whether the results are preliminary or final. Figures and Tables: Figures, tables, or other illustrations that exceeded the abstract submission guidelines were removed from the submitted abstract and are not included in the Abstract eBook. For examples and for additional information on this review process, visit the Common Reasons for Removal webpage. New Compounds: For abstracts describing new compounds, the chemical or molecular structure must be shown in the presentation. It need not be part of the abstract or be published in the Abstract eBook. Sex and Gender: Appropriate information and correct terminology should be used with regard to sex and gender. For human clinical or epidemiologic studies, the presentation should provide sex stratified results or identify who was included if it only included only a single population. Appropriate terminology such as “cisgender” (people whose gender matches the sex assigned at birth) or “transgender” (people whose gender does not match the sex assigned at birth) should be used. Both sex and gender data should be provided in the presentation. Presentations of preclinical data, including the use of cell lines and animal studies should include the sex of the animals or the sex of the source of the cell lines. If data are not available on sex and gender, this should be identified as a limitation in your presentation. Person-First Language and Appropriate Terminology: CROI strongly advocates for the use of and strives to incorporate “people first” language and acceptable terminology in all CROI-related materials and presentations. All abstract authors and presenters should apply the following basic principles of appropriate language and terminology including: • Describe populations as “people, persons, or individuals with HIV” rather than “HIV-infected people, persons, or individuals.” • Do not characterize people by their disease, infection, or condition; instead, use “people who inject drugs,”“individuals with cirrhosis,” or other similar constructs. • Out of respect for their contributions to our scientific advances, do not describe people enrolled in research studies or clinical trials as “subjects” or “patients.” Acceptable terms include research study or clinical trial “participants” or “volunteers.”

• Do not use the term “sterilizing” when referring to HIV cure; it triggers a negative perception in many people due to historic sterilization campaigns and may discourage participation in research. Abstract Review Process For more information, visit the Abstract Guidelines and Submission webpage. Statistics for Abstracts General Abstracts Submitted ��������������������������������������������������������� 1682 General Abstracts Accepted ������������������������������������������������������������� 966 Late-Breaking Abstracts Submitted ������������������������������������������������ 220 Late-Breaking Abstracts Accepted ��������������������������������������������������� 101 Total Abstracts Accepted ������������������������������������������������������������ 1067 Ora Abstract Presentations ������������������������������������������������������� 111 Themes Discussion Presentations ��������������������������������������������� 54 Poster Presentations ����������������������������������������������������������������������956 Accepted Abstracts for Emerging Infections or Specific Populations SARS-CoV-2 ����������������������������������������������������������������������������������������� 193 Mpox ����������������������������������������������������������������������������������������������������� 33 Adolescents ����������������������������������������������������������������������������������������� 137 Men who have sex with men (MSM) ����������������������������������������������� 220 People Who Inject Drugs (PWID) ������������������������������������������������������� 84 Transgender Men or Women ������������������������������������������������������������� 84 Women or girls ����������������������������������������������������������������������������������� 259

Abstract Process

Please note: Figures, tables, or other graphics have been removed from the following abstracts due to noncompliance with the CROI Abstract Guidelines: 121, 133, 136, 175, 195, 209, 319, 336, 339, 345, 349, 359, 388, 424, 442, 490, 507, 510, 511, 530, 531, 534, 538, 549, 554, 557, 559, 561, 573, 594, 596, 602, 618, 629, 632, 658, 661, 662, 670, 694, 714, 721, 722, 726, 736, 741, 745, 761, 762, 764, 778, 781, 782, 794, 796, 803, 807, 812, 813, 824, 826, 843, 845, 860, 901, 923, 928, 947, 952, 968, 991, 1005, 1009, 1032, 1037, 1046, 1069, 1072, 1077, 1086, 1090, 1095, 1097, 1104, 1119, 1124, 1145, 1146, 1148, 1162, 1169, 1172, 1179, 1186, 1197, 1205, 1212, 1224, 1225, 1240, 1248

5

CROI 2024

Made with FlippingBook. PDF to flipbook with ease